MondegarAI
PFIZER INC (PFE)

Q4 2025 · 13F-HR

PFIZER INC (PFE)holdings as filed

Filed 2026-02-12 · accession 0000078003-26-000013

$236.5M
Reported value
18
Positions
2025-12-31
Period end
View analyzed profile →PRO

The Brief · PFIZER INC (PFE) · Q4 2025

AI · grounded in 13F

PFIZER INC (PFE) closed its position in BIONTECH SE BNTX, reducing its holdings by $163.5M. The fund also exited its position in TOURMALINE BIO INC TRML for $60.8M and closed its stake in ESSA PHARMA INC EPIEUR valued at $319,925. Additionally, the fund trimmed its position in SENSEONICS HLDGS INC SENS1GBP by 95%.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
68622P109ORICORIC PHARMACEUTICALS INC$44.0M18.6%5,376,344CommonSOLE
04335A105ARVNARVINAS INC$41.0M17.3%3,457,815CommonSOLE
15102K100CELCCELCUITY INC$34.8M14.7%349,406CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$31.9M13.5%1,875,000CommonSHARED
019770106ALLOALLOGENE THERAPEUTICS INC$30.2M12.8%22,032,040CommonSOLE
G9TY5A101ZURAZURA BIO LTD$15.6M6.58%2,970,022CommonSOLE
747324101PYXSPYXIS ONCOLOGY INC$8.1M3.42%7,032,770CommonSOLE
142038108CRBUCARIBOU BIOSCIENCES INC$7.5M3.15%4,690,431CommonSOLE
14147L108CRDFCARDIFF ONCOLOGY INC$6.8M2.87%2,411,575CommonSOLE
G1110E107BHVNBIOHAVEN LTD$5.7M2.41%505,645CommonSOLE
84833T103SPROSPERO THERAPEUTICS INC$5.5M2.33%2,362,348CommonSOLE
65343E207NXTCNEXTCURE INC$2.2M0.95%157,646CommonSOLE
98943L107ZNTLZENTALIS PHARMACEUTICALS INC$1.3M0.54%953,834CommonSOLE
746964105QTTBQ32 BIO INC$922,2200.39%277,777CommonSOLE
037326105ANTXAN2 THERAPEUTICS INC$815,4360.34%715,295CommonSHARED
097702203BOLTBOLT BIOTHERAPEUTICS INC$171,1760.07%31,305CommonSHARED
37611X209DNAGINKGO BIOWORKS HOLDINGS INC$24,3320.01%2,928CommonSOLE
81727U105SENS1GBPSENSEONICS HLDGS INC$11,9830.01%2,171CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.